Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 37

Sort by

Sort Order Select

Journal Articles

131 I-Apamistamab-Led Allogeneic Hematopoietic Cell Transplant Significantly Improves Overall Survival in Patients with TP53 Mutated R/R AML

Blood (2023) 142 (Supplement 1): 469.

https://doi.org/10.1182/blood-2023-182177

Published: 2023

Journal Articles

131 I-Apamistamab Effectively Achieved Durable Responses in Patients with R/R AML Irrespective of the Presence of Multiple High-Risk Factors

Blood (2023) 142 (Supplement 1): 2159.

https://doi.org/10.1182/blood-2023-187433

Published: 2023

Journal Articles

Low-Dose Decitabine Plus Venetoclax As Post-Transplant Maintenance for High-Risk Myeloid Malignancies

Katherine Parks, Kendall Diebold, Donna Salzman, Antonio Di Stasi, Manuel Espinoza-Gutarra, Ravi Bhatia, Zaid Al-Kadhimi, Omer Jamy

Blood (2023) 142 (Supplement 1): 7052.

https://doi.org/10.1182/blood-2023-184658

Published: 2023

Journal Articles

High-Dose Targeted Radiation with 131 I-Apamistamab Prior to HCT Demonstrated a Dose-Response for Durable Complete Remission in Patients with R/R AML

Blood (2023) 142 (Supplement 1): 3529.

https://doi.org/10.1182/blood-2023-189040

Published: 2023

Journal Articles

Addition of Single Dose Gemtuzumab Ozogamicin to Intensive Induction Chemotherapy in Core-Binding Factor Acute Myeloid Leukemia

Garrett Bourne, Kendall Diebold, Manuel Espinoza-Gutarra, Zaid Al-Kadhimi, Kimo Bachiashvili, Sravanti Rangaraju, Pankit Vachhani, Ravi Bhatia, Omer Jamy

Blood (2023) 142 (Supplement 1): 5848.

https://doi.org/10.1182/blood-2023-189853

Published: 2023

Journal Articles

Idarubicin and Cytarabine with and without Midostaurin for FLT3-Mutated Acute Myeloid Leukemia

Kendall Diebold, Sarah Worth, Kimo Bachiashvili, Pankit Vachhani, Sravanti Rangaraju, Manuel Espinoza-Gutarra, Zaid Al-Kadhimi, Ravi Bhatia, Omer Jamy

Blood (2023) 142 (Supplement 1): 5910.

https://doi.org/10.1182/blood-2023-185198

Published: 2023

Journal Articles

Improving Outcomes in Elderly Acute Promyelocytic Leukemia Patients in the Real World: A Personalized Treatment Approach Along with Expert Support Might Reduce Early Deaths

Blood (2017) 130 (Supplement 1): 5667.

https://doi.org/10.1182/blood.V130.Suppl_1.5667.5667

Published: 2017

Journal Articles

Assessing Individual Comorbidities in Elderly Non-Hodgkin Lymphoma Patients Undergoing Autologous Stem Cell Transplant — Obesity Associated with Inferior Outcomes

Andrew Ip, MD, Jeffrey M. Switchenko, PhD MS, Michael Graiser, Jean L. Koff, MD, Vikas A. Gupta, MD PhD, Ajay K. Nooka, MDMPH, Zaid Al-Kadhimi, MD, Mary Jo Lechowicz, MD, Jonathan L. Kaufman, MD, Sagar Lonial, MD, Edmund K. Waller, MD, Amelia Langston, MD, Christopher Flowers, MD, Jonathon B Cohen, MDMS

Blood (2017) 130 (Supplement 1): 5516.

https://doi.org/10.1182/blood.V130.Suppl_1.5516.5516

Published: 2017

Journal Articles

A Multi-Center Prospective Study Utilizing a Simplified Treatment Algorithm Complemented By Expert Support Decreases Induction Mortality and Improves Survival in Acute Promyelocytic Leukemia (APL). Results of the APL Trial in Georgia, South Carolina and Neighboring States

Blood (2016) 128 (22): 2793.

https://doi.org/10.1182/blood.V128.22.2793.2793

Published: 2016

Journal Articles

A Prospective Multi-Center Trial Shows Reduction of Early Deaths (ED) and Improved Survival in Elderly Acute Promyelocytic Leukemia (APL) Patients (>60 years). Results of Using a Simplified Treatment Algorithm and Expert Support in Georgia, South Carolina and Neighboring States

Blood (2016) 128 (22): 1622.

https://doi.org/10.1182/blood.V128.22.1622.1622

Published: 2016

Journal Articles

Ruxolitinib As Sparing Agent for Steroid-Dependent Chronic Graft-Versus-Host Disease (cGVHD)

H. Jean Khoury, Vamsi Kota, M.B;B.S, Martha Arellano, MD, Stephanie L Bauer, ANP, Anand P Jillella, MD, Amelia Langston, MD, Zaid Al-Kadhimi, MD, Zachariah DeFilipp, MD, Audrey S Kim, RN, Elliott F. Winton, MD, John F Dipersio, MD PhD

Blood (2015) 126 (23): 1938.

https://doi.org/10.1182/blood.V126.23.1938.1938

Published: 2015

Journal Articles

TLR5 Agonist Recombinant Flagellin, CBLB502 Increases Anti-CMV Immunity By Increasing T-Bet and Eomes Expressing T Cells after MCMV Infection

Mohammad Sohrab Hossain, PhD, Zaid Al-Kadhimi, MD, Edmund K Waller, MD PhD

Blood (2015) 126 (23): 3082.

https://doi.org/10.1182/blood.V126.23.3082.3082

Published: 2015

Journal Articles

Incidence, Risk Factors and Outcome Of Cytomegalovirus (CMV) Viremia and CMV Gastroenteritis In Patients With Gastrointestinal Graft Versus Host Disease (GI GVHD)

Divaya Bhutani, MD, Gregory Dyson, MS, Richard Manasa, BS, Voravit Ratanatharathorn, MD, Abhinav Deol, MD, Muneer H. Abidi, MD, Zaid Al-Kadhimi, MD, Lois Ayash, MD, Lawrence G Lum, MD, DSc, Joseph P. Uberti, MD, PhD

Blood (2013) 122 (21): 2039.

https://doi.org/10.1182/blood.V122.21.2039.2039

Published: 2013

Journal Articles

Antithymocyte Globulin (Rabbit) Enhanced The Efficacy Of Tacrolimus and Mycophenolate For Graft-Versus-Host Disease Prophylaxis In Recipients Of Unrelated Stem Cell Transplant Resulting In Improvement Of Survival

Voravit Ratanatharathorn, MD, Abhinav Deol, MD, Lois Ayash, MD, Divaya Bhutani, MD, Lawrence G Lum, MD, DSc, Zaid Al-Kadhimi, MD, Muneer H. Abidi, MD, Marie Ventimiglia, Kendra Mellert, Joseph P. Uberti, MD, PhD

Blood (2013) 122 (21): 3300.

https://doi.org/10.1182/blood.V122.21.3300.3300

Published: 2013

Journal Articles

Low Incidence Of Severe Cgvhd and Late NRM In a Phase II Trial Of Thymoglobulin®, Tacrolimus and Sirolimus For Gvhd Prevention

Zaid Al-Kadhimi, MD, Alireza Eghtedar, MD, Zartash Gul, MD, Wei Chen, PhD, Daryn Smith, Abhinav Deol, MD, Muneer H. Abidi, MD, Lawrence G Lum, MD, DSc, Divaya Bhutani, MD, Lois Ayash, MD, Voravit Ratanatharathorn, MD, Joseph P. Uberti, MD, PhD

Blood (2013) 122 (21): 5471.

https://doi.org/10.1182/blood.V122.21.5471.5471

Published: 2013

Journal Articles

Induction Of Anti-Myeloma Cellular and Humoral Immunity By Pre-Targeting Clonogenic Myeloma Cells Prior To Stem Cell Transplant With T Cells Armed With Anti-CD3 x Anti-CD20 Bispecific Antibody Leads To Transfer Of Cellular and Humoral Anti-Myeloma Immunity

Lawrence G Lum, MD, DSc, Archana Thakur, PhD, Zaid Al-Kadhimi, MD, Abhinav Deol, MBBS, MD, Lois Ayash, MD, Elyse N. Tomaszewski, BA, Hiroshi Yano, BS, Dana L Schalk, BS, MBA, Sri Vidya Kondadasula, MS, Patricia A. Steele, RN, BSN, Jeffrey A. Zonder, MD, Joseph P. Uberti, MD, PhD, Voravit Ratanatharathorn, MD, Muneer H. Abidi, MD

Blood (2013) 122 (21): 139.

https://doi.org/10.1182/blood.V122.21.139.139

Published: 2013

Journal Articles

High Rates of Severe aGVHD with Tacrolimus and Mycophenolate Mofetil in a Large Cohort of Related and Unrelated Allogeneic Transplant Patients

Zaid Al-Kadhimi, MD, Zartash Gul, MD, Wei Chen, PhD, Daryn Smith, Abhinav Deol, MD, Muneer H. Abidi, MD, Lois Ayash, MD, Lawrence G Lum, MD, DSc, Voravit Ratanatharathorn, MD, Joseph P. Uberti, MD, PhD

Blood (2012) 120 (21): 1951.

https://doi.org/10.1182/blood.V120.21.1951.1951

Published: 2012

Journal Articles

Successful Hematopoietic Stem Cells (HSC) Mobilization in Patients Who Fail Plerixafor Mobilization for Autologous Stem Cells Transplant (ASCT)

Tania Jain, MD, Muthu Veeraputhiran, MD, Simon Cronin, Pharm, D, Zaid Al-Kadhimi, MD, Muneer H. Abidi, MD, Lois Ayash, MD, Voravit Ratanatharathorn, MD, Lawrence G Lum, MD, DSc, Joseph P. Uberti, MD, PhD, Abhinav Deol, MD

Blood (2012) 120 (21): 1913.

https://doi.org/10.1182/blood.V120.21.1913.1913

Published: 2012

Journal Articles

Transfer of Cellular and Humoral Anti-Tumor Immunity with Immune T Cells After Stem Cell Transplant (SCT) for Metastatic Breast Cancer Following “Vaccination” with Anti-CD3 x Anti-Her2/Neu Bispecific Antibody (Her2Bi) Armed Activated T Cells

Archana Thakur, PhD, Zaid Al-Kadhimi, MD, Cassara Pray, BS, Elyse N. Tomaszewski, BA, Ritesh Rathore, MD, Patricia A. Steele, RN, BSN, Muneer H. Abidi, MD, Lois Ayash, MD, Dana L Schalk, BS, MBA, Karen Myers, BSN, OCN, Alice Mitchell, BS, Abhinav Deol, MD, Joseph P. Uberti, MD, PhD, Voravit Ratanatharathorn, MD, Lawrence G Lum, MD, DSc

Blood (2011) 118 (21): 1914.

https://doi.org/10.1182/blood.V118.21.1914.1914

Published: 2011

Journal Articles

Use of Plerixafor to Overcome Stem Cell Mobilization Failure: Long Term Follow up of Patients Proceeding to Transplant Using Plerixafor Mobilized Stem Cells

Abhinav Deol, MD, Judith Abrams, PhD, Ashiq Masood, MD, Zaid Al-Kadhimi, MD, Muneer H. Abidi, MD, Lois Ayash, MD, Voravit Ratanatharathorn, MD, Lawrence G Lum, MD, DSc, Joseph P. Uberti, MD, PhD

Blood (2011) 118 (21): 4390.

https://doi.org/10.1182/blood.V118.21.4390.4390

Published: 2011

NARROW

131 I-Apamistamab-Led Allogeneic Hematopoietic Cell Transplant Significantly Improves Overall Survival in Patients with TP53 Mutated R/R AML

131 I-Apamistamab Effectively Achieved Durable Responses in Patients with R/R AML Irrespective of the Presence of Multiple High-Risk Factors

Low-Dose Decitabine Plus Venetoclax As Post-Transplant Maintenance for High-Risk Myeloid Malignancies

High-Dose Targeted Radiation with 131 I-Apamistamab Prior to HCT Demonstrated a Dose-Response for Durable Complete Remission in Patients with R/R AML

Addition of Single Dose Gemtuzumab Ozogamicin to Intensive Induction Chemotherapy in Core-Binding Factor Acute Myeloid Leukemia

Idarubicin and Cytarabine with and without Midostaurin for FLT3-Mutated Acute Myeloid Leukemia

Improving Outcomes in Elderly Acute Promyelocytic Leukemia Patients in the Real World: A Personalized Treatment Approach Along with Expert Support Might Reduce Early Deaths

Assessing Individual Comorbidities in Elderly Non-Hodgkin Lymphoma Patients Undergoing Autologous Stem Cell Transplant — Obesity Associated with Inferior Outcomes

A Multi-Center Prospective Study Utilizing a Simplified Treatment Algorithm Complemented By Expert Support Decreases Induction Mortality and Improves Survival in Acute Promyelocytic Leukemia (APL). Results of the APL Trial in Georgia, South Carolina and Neighboring States

A Prospective Multi-Center Trial Shows Reduction of Early Deaths (ED) and Improved Survival in Elderly Acute Promyelocytic Leukemia (APL) Patients (>60 years). Results of Using a Simplified Treatment Algorithm and Expert Support in Georgia, South Carolina and Neighboring States

Ruxolitinib As Sparing Agent for Steroid-Dependent Chronic Graft-Versus-Host Disease (cGVHD)

TLR5 Agonist Recombinant Flagellin, CBLB502 Increases Anti-CMV Immunity By Increasing T-Bet and Eomes Expressing T Cells after MCMV Infection

Incidence, Risk Factors and Outcome Of Cytomegalovirus (CMV) Viremia and CMV Gastroenteritis In Patients With Gastrointestinal Graft Versus Host Disease (GI GVHD)

Antithymocyte Globulin (Rabbit) Enhanced The Efficacy Of Tacrolimus and Mycophenolate For Graft-Versus-Host Disease Prophylaxis In Recipients Of Unrelated Stem Cell Transplant Resulting In Improvement Of Survival

Low Incidence Of Severe Cgvhd and Late NRM In a Phase II Trial Of Thymoglobulin®, Tacrolimus and Sirolimus For Gvhd Prevention

Induction Of Anti-Myeloma Cellular and Humoral Immunity By Pre-Targeting Clonogenic Myeloma Cells Prior To Stem Cell Transplant With T Cells Armed With Anti-CD3 x Anti-CD20 Bispecific Antibody Leads To Transfer Of Cellular and Humoral Anti-Myeloma Immunity

High Rates of Severe aGVHD with Tacrolimus and Mycophenolate Mofetil in a Large Cohort of Related and Unrelated Allogeneic Transplant Patients

Successful Hematopoietic Stem Cells (HSC) Mobilization in Patients Who Fail Plerixafor Mobilization for Autologous Stem Cells Transplant (ASCT)

Transfer of Cellular and Humoral Anti-Tumor Immunity with Immune T Cells After Stem Cell Transplant (SCT) for Metastatic Breast Cancer Following “Vaccination” with Anti-CD3 x Anti-Her2/Neu Bispecific Antibody (Her2Bi) Armed Activated T Cells

Use of Plerixafor to Overcome Stem Cell Mobilization Failure: Long Term Follow up of Patients Proceeding to Transplant Using Plerixafor Mobilized Stem Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only